

19 July 2018

Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the "Group")

Oxford BioDynamics announces grant of Canadian patent for its proprietary technology platform, *EpiSwitch*[™]

Oxford BioDynamics Plc ("OBD" or the "Company"), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, today announces the grant of a key patent by the Canadian Intellectual Property Office covering *EpiSwitch*[™], the Company's novel technology platform.

The Canadian patent, number 2642331, covers OBD's proprietary *EpiSwitch*[™] technology designs for high resolution discovery and monitoring of regulatory conditional chromosome conformation signatures, as part of the regulatory architecture of the genome. As a biomarker modality, chromosome conformations have been shown to deliver highly informative stratifications of complex patient phenotypes, assist in better disease understanding and target identifications, and show high concordance with complex genetic and gene expression profiles. Predictive and prognostic stratifications developed by OBD on the basis of its proprietary *EpiSwitch*[™] technology already offer significant improvements in patient stratifications, de-risking of drug discovery and development, and upgraded regulatory and market protection.

This patent will further extend coverage of OBD's proprietary technology platform, *EpiSwitch*[™], in this important market. Counterparts to this patent have already been granted in the USA, Europe, China, Japan, Australia, India, Hong Kong, New Zealand, Singapore and South Africa.

Christian Hoyer Millar, Chief Executive Officer of Oxford BioDynamics, commented:

*"We are pleased with the addition of this patent covering the use of our *EpiSwitch*[™] technology in the Canadian market. This patent strengthens our global intellectual property position and further validates our novel approach to characterising structural modifications to genome architecture that have a profound effect on health."*

-ENDS-

For further details please contact:

Oxford BioDynamics Plc +44 (0)1865 518910
Christian Hoyer Millar, CEO
Paul Stockdale, CFO

Shore Capital +44 (0)20 7408 4090
Broker and Nominated Adviser
Stephane Auton
Edward Mansfield

FTI Consulting +44 (0)20 3727 1000
Financial Public Relations Adviser
Brett Pollard
Natalie Garland-Collins

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.

The Company's award-winning, proprietary technology platform, *EpiSwitch*[™], aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.

In particular, *EpiSwitch*[™] can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re-positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.